BRCA2 and breast carcinoma: There was evidence for a PRSxage interaction for the ER-negative breast cancer PRS for BRCA1 carriers (P = 3×10−6) and for the overall breast cancer PRS for BRCA2 carriers (P = .01) (Table 3).